The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ACADEMIA
New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia
The new guidelines being drafted by the Japan Atherosclerosis Society, due out in 2017, are expected to recommend the use of PCSK9 inhibitors for the primary prevention of coronary artery disease (CAD) in familial hypercholesterolemia (FH), Shizuya Yamashita, head of…
To read the full story
Related Article
- 1st Line Statins Likely to Be Recommended for Pediatric Familial Hypercholesterolemia
July 21, 2016
- Discussions on New Guidelines for Atherosclerosis Prevention Get Underway
February 9, 2016
- JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL
February 7, 2012
ACADEMIA
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…